SecBot SecBot
Insider Cluster (2 insiders) ·Filed Sep 10, 2026

JAZZ

Jazz Pharmaceuticals plc
NEUTRAL
Impact 2/10
Horizondays Processed1mo ago
Insider cluster: 2 insiders, $2.0M total
Actionable Insight • Neutral

This cluster is too small to warrant a trading signal. Monitor for any material insider sales exceeding 0.5% of market cap or a pattern of sustained C-suite selling.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+20d
JAZZ ▼ -11.14% at T+20d
NEUTRAL call -11.14% · α vs SPY -13.01% · entry $245.80 → $218.42
Next anchor: T+60d in 6w
Latest observation: T+30 -13.96% FF3 residual α
Entry = T+0 close
Sep 10, 2026
via day close
T+1d
+0.03%
call +0.03% · α +0.47%
$245.87
settled 6w ago
T+5d
-2.06%
call -2.06% · α -1.72%
$240.74
settled 6w ago
T+20d
-11.14%
call -11.14% · α -13.01%
$218.42
settled 18d ago
T+60d
Pending
in 6w

Price Chart

Loading chart...

Executive Summary

A small insider selling cluster at Jazz Pharmaceuticals, with the CEO and a director selling a combined ~$2M in open-market sales over a 7-day window. The total value represents ~0.01% of the $15.7B market cap, well below the 0.1% threshold for materiality. The CEO's sale is modest relative to her holdings, and the director's sale is routine in size. No bearish signal is warranted — these are likely liquidity or diversification trades, not informed selling.

Key Financial Metrics

Direction
selling
Total Value
$2.0M
Insiders
2

Key Facts

  • CEO Renee D. Gala sold 2,000 shares open-market for ~$486K on 2026-09-08
  • Director Bruce C. Cozadd sold 6,000 shares open-market for ~$1.50M on 2026-09-01
  • Total open-market sales of ~$1.99M represent ~0.01% of $15.7B market cap
  • Two additional tax-withholding transactions (non-cash) by SVP Henderson and CEO Gala total ~$832K in shares surrendered
  • No insider buying in the cluster — net direction is selling

Financial Impact

Total open-market sales of ~$1.99M, or ~0.01% of market cap — immaterial

dilution

Risk Factors

  • Insider selling could accelerate if management sees headwinds not yet public
  • No buying activity to offset the selling signal

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (26 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-JAZZ-1789106714205
28 reports for JAZZ
Performance horizon
60% Hit rate @ T+1 3 of 5 directional calls Went positive at some point 4 of 5 best @ T+60▲ +22.04%Feb 24, 2026
Filters
Rows
Reports for JAZZ — sortable, filterable
TypeNow
Oct 19, 2026
6d ago
Press Release
NEUTRAL ★ 1/10
$213.76 $211.97▼ −0.84%▼ −1.36%$210.99 (−1.30%)
Oct 9, 2026
17d ago
8-K
NEUTRAL ★ 2/10
$218.42 $216.75▼ −0.76%▼ −0.70%$210.99 (−3.40%)
Oct 8, 2026
17d ago
144
NEUTRAL ★ 2/10
$218.42 $216.75▼ −0.76%▼ −0.70%$210.99 (−3.40%)
Oct 6, 2026
19d ago
144
NEUTRAL ★ 2/10
$231.19 $222.45▼ −3.78%▼ −3.36%$210.99 (−8.74%)
Oct 1, 2026
24d ago
144
NEUTRAL ★ 2/10
$235.67 $236.04▲ +0.16%▼ −0.52%$210.99 (−10.47%)
Sep 15, 2026
5w ago
8-K
BULLISH ★ 6/10
$240.83 $243.59▲ +1.15%▲ +1.59%$210.99 (−12.39%)
Sep 14, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$240.83 $243.59▲ +1.15%▲ +1.59%$210.99 (−12.39%)
Sep 10, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$245.80 $245.87▲ +0.03%▲ +0.47%$210.99 (−14.16%)
Sep 2, 2026
7w ago
Insider Cluster
BEARISH ★ 4/10
$247.57 $246.81▲ +0.30%▼ −0.08%$210.99 (+14.78%)
Aug 31, 2026
7w ago
144
NEUTRAL ★ 2/10
$243.71 $245.57▲ +0.76%▲ +0.32%$210.99 (−13.43%)
Showing 10 of 28

US Market Status

Market Open — Closes in 5h 16m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 11, 2026